Synthesis and nicotinic binding of novel phenyl derivatives of UB-165. Identifying factors associated with α7 selectivity

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 17, 2003, Pages 2825-2828

  Karig, Gunter ^a   Large, Jonathan M ^a   Sharples, Christopher G V ^b   Sutherland, Andrew ^a   Gallagher, Timothy ^a   Wonnacott, Susan ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b University of Bath   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZENE DERIVATIVE; NICOTINIC AGENT; NICOTINIC RECEPTOR; RECEPTOR SUBTYPE; UB 165; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN; CHEMICAL REACTION; COMPARATIVE STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; ISOTOPE LABELING; NONHUMAN; PHARMACOPHORE; RAT; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

EID: 0242578258     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00594-8     Document Type: Article

References (25)

1. Role L.W., Berg D.K. Neuron. 16:1996;1077.
2. Lindstrom J. Mol. Neurobiol. 15:1997;193.
3. Arneric S.P., Brioni J.D. Neuronal Nicotinic Receptors. 1999;John Wiley and Sons, New York.
4. Jones S., Sudweeks S., Yakel J.L. Trends Neurosci. 22:1999;555.
5. Paterson D., Nordberg A. Prog. Neurobiol. 61:2000;75.
6. Curtis L., Chiodini F., Spang J.E., Bertrand S., Patt J.T., Westera G., Bertrand D. Eur. J. Pharmacol. 393:2000;155.
7. Bannon A.W., Decker M.W., Holladay M.W., Curzon P., Donnelly-Roberts D., Puttfarcken P.S., Bitner R.S., Diaz A., Dickenson A.H., Porsolt R.D., Williams M., Arneric S.P. Science. 279:1998;77.
8. Holladay M.W., Dart M.J., Lynch J.K. J. Med. Chem. 40:1997;4169.
9. Lloyd G.K., Williams M. J. Pharmacol. Exp. Ther. 292:2000;461.
10. Wright E., Gallagher T., Sharples C.G.V., Wonnacott S. Bioorg. Med. Chem. Lett. 7:1997;2867.
11. Sharples C.G.V., Kaiser S., Soliakov L., Marks M.J., Collins A.C., Washburn M., Wright E., Spencer J.A., Gallagher T., Whiteaker P., Wonnacott S. J. Neurosci. 20:2000;2783.
12. Sharples C.G.V., Karig G., Simpson G.L., Spencer J.A., Wright E., Millar N.S., Wonnacott S., Gallagher T. J. Med. Chem. 45:2002;3235.
13. Gohlke H., Gundisch D., Schwarz S., Seitz G., Tilotta M.C., Wegge T. J. Med. Chem. 45:2002;1064.
14. Gribble G.W., Saulnier M.G. Tetrahedron Lett. 21:1980;4137.
15. Karig G., Spencer J.A., Gallagher T. Org. Lett. 3:2001;835.
16. Karig G., Thasana N., Gallagher T. Synlett. 2002;808.
17. Lewis T.M., Harkness P.C., Sivilotti L.G., Colquhoun D., Millar N.S. J. Physiol. 505:1997;299.
18. Tønder J.E., Olesen P.H., Hansen J.B., Begtrup M., Pettersson I. J. Comput.-Aided Mol. Des. 15:2001;247.
19. Tønder J.E., Olesen P.H. Curr. Med. Chem. 8:2001;651.
20. Dukat M., Damaj M.I., Glassco W., Dumas D., May E.L., Martin B.R., Glennon R.A. Med. Chem. Res. 4:1993;131.
21. Glennon R.A., Herndon J.A., Dukat M. Med. Chem. Res. 6:1994;465.
22. Meyer M.D., Decker M.W., Rueter L.E., Anderson D.J., Dart M.J., Kim K.H., Sullivan J.P., Williams M. Eur. J. Pharmacol. 393:2000;171.
23. 12.
24. 25 has reported binding data for 6-phenyl nicotine and the corresponding homoazanicotine analogue (cf. ligand 6), both of which show low affinity for the α4β2 nAChR. The corresponding quinolines show somewhat increased levels of potency.
25. Ferretti G., Dukat M., Giannella M., Piergentili A., Pigini M., Quaglia W., Damaj M.I., Martin B.R., Glennon R.A. Bioorg. Med. Chem. Lett. 13:2003;733.